The management of Peyronie's disease

D J Ralph1, S Minhas

  • 1St Peter's Hospitals and The Institute Of Urology, London, UK. dralph@andrology.co.uk

BJU International
|December 24, 2003
PubMed

Insights

Peyronie's disease lacks a clear cause, but understanding its molecular basis and using animal models can improve early treatment. Chronic cases are untreatable, requiring surgery for penile deformities.

Area of Science:

  • Urology
  • Molecular Biology
  • Animal Modeling

Background:

  • Peyronie's disease etiology remains unknown.
  • Current medical management for chronic Peyronie's disease is ineffective due to irreversible tunical damage.
  • Surgical intervention is necessary for a subset of patients with significant penile deformity.

Purpose of the Study:

  • To explore the molecular mechanisms underlying Peyronie's disease.
  • To develop an animal model for studying Peyronie's disease.
  • To improve the medical management of early-stage Peyronie's disease.

Main Methods:

  • Investigation of molecular pathways involved in Peyronie's disease pathogenesis.
  • Development and validation of a preclinical animal model.
  • Review of treatment options for chronic Peyronie's disease.

Main Results:

  • Understanding molecular mechanisms offers potential for early disease intervention.
  • An established animal model facilitates research into disease progression and treatment efficacy.
  • Chronic Peyronie's disease management is limited, with surgery being the primary option.

Conclusions:

  • Advances in understanding molecular mechanisms and animal modeling are crucial for improving early Peyronie's disease management.
  • Medical treatment for chronic Peyronie's disease is not viable.
  • Surgical options like the Nesbit operation or plaque incision with venous grafting are available for patients concerned about penile shortening.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...